Wilson Kevin S.

Avg. Two Year Performance

No purchase track record
(83%) Avg. Sale Return
(35%) Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return0%0%0%0%0%
Purchase Success Rate0 of 10 of 10 of 10 of 10 of 1
Average Sale Return(7%)(24%)(53%)(68%)(83%)
Sale Success Rate7 of 165 of 163 of 163 of 161 of 16

Heska Corp.

Drugs » Biotechnology

CEO and President, Director:

Holdings: 0 shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--